Combination studies with gemcitabine in the treatment of non-small-cell lung cancer
1998

Combination Studies with Gemcitabine in Non-Small-Cell Lung Cancer

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): WP Steward

Primary Institution: University Department of Oncology, Leicester Royal Infirmary

Hypothesis

Gemcitabine can be effectively combined with other agents to improve treatment outcomes in non-small-cell lung cancer.

Conclusion

Gemcitabine combined with cisplatin shows promising response rates and manageable toxicity in treating non-small-cell lung cancer.

Supporting Evidence

  • Response rates for gemcitabine and cisplatin combinations ranged from 32% to 54%.
  • The median survival for patients treated with gemcitabine and cisplatin was between 8.4 and 14.3 months.
  • Neutropenia and thrombocytopenia were the most common side effects, but they were manageable.

Takeaway

Gemcitabine is a medicine that helps treat lung cancer, and when used with another medicine called cisplatin, it can help more people get better.

Methodology

Phase II studies evaluated the effectiveness and safety of gemcitabine in combination with cisplatin in patients with non-small-cell lung cancer.

Limitations

The studies had varying patient demographics and treatment schedules, which may affect the generalizability of the results.

Participant Demographics

Patients were primarily elderly, with a median age around 59-64 years, and included those with advanced stages of non-small-cell lung cancer.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication